Cargando…
Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038489/ https://www.ncbi.nlm.nih.gov/pubmed/33916569 http://dx.doi.org/10.3390/jcm10071503 |
_version_ | 1783677387259510784 |
---|---|
author | Cantini, Luca Bastianelli, Lucia Lupi, Alessio Pinterpe, Giada Pecci, Federica Belletti, Giovanni Stoico, Rosa Vitarelli, Francesca Moretti, Marco Onori, Nicoletta Giampieri, Riccardo Rocchi, Marco Bruno Luigi Berardi, Rossana |
author_facet | Cantini, Luca Bastianelli, Lucia Lupi, Alessio Pinterpe, Giada Pecci, Federica Belletti, Giovanni Stoico, Rosa Vitarelli, Francesca Moretti, Marco Onori, Nicoletta Giampieri, Riccardo Rocchi, Marco Bruno Luigi Berardi, Rossana |
author_sort | Cantini, Luca |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs. |
format | Online Article Text |
id | pubmed-8038489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80384892021-04-12 Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy Cantini, Luca Bastianelli, Lucia Lupi, Alessio Pinterpe, Giada Pecci, Federica Belletti, Giovanni Stoico, Rosa Vitarelli, Francesca Moretti, Marco Onori, Nicoletta Giampieri, Riccardo Rocchi, Marco Bruno Luigi Berardi, Rossana J Clin Med Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of this observational, prospective study was to assess the seroprevalence of SARS-CoV-2 IgM/IgG antibodies in solid cancer patients referred to the academic institution of the Marche Region, Italy, between 1 July and 26 October 2020 and to determine the accuracy of the rapid serological test. After performing 3767 GCCOV-402a rapid serological tests on a total of 949 patients, seroconversion was initially observed in 13 patients (1.4%). Ten (77% of the total positive) were IgG-positive, 1 (8%) were IgM-positive and 2 (15%) IgM-positive/IgG-positive. However, only 7 out of 13 were confirmed as positive at the reference serological test (true positives), thus seroprevalence after cross-checking was 0.7%. No false negatives were reported. The kappa value of the consistency analysis was 0.71. Due to rapid serological test high false positive rate, its role in assessing seroconversion rate is limited, and the standard serological tests should remain the gold standard. However, as rapid test negative predictive value is high, GCCOV-402a may instead be useful to monitor patient immunity over time, thus helping to assist ongoing vaccination programs. MDPI 2021-04-04 /pmc/articles/PMC8038489/ /pubmed/33916569 http://dx.doi.org/10.3390/jcm10071503 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cantini, Luca Bastianelli, Lucia Lupi, Alessio Pinterpe, Giada Pecci, Federica Belletti, Giovanni Stoico, Rosa Vitarelli, Francesca Moretti, Marco Onori, Nicoletta Giampieri, Riccardo Rocchi, Marco Bruno Luigi Berardi, Rossana Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title | Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title_full | Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title_fullStr | Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title_full_unstemmed | Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title_short | Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy |
title_sort | seroprevalence of sars-cov-2–specific antibodies in cancer patients undergoing active systemic treatment: a single-center experience from the marche region, italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038489/ https://www.ncbi.nlm.nih.gov/pubmed/33916569 http://dx.doi.org/10.3390/jcm10071503 |
work_keys_str_mv | AT cantiniluca seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT bastianellilucia seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT lupialessio seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT pinterpegiada seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT peccifederica seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT bellettigiovanni seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT stoicorosa seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT vitarellifrancesca seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT morettimarco seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT onorinicoletta seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT giampieririccardo seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT rocchimarcobrunoluigi seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly AT berardirossana seroprevalenceofsarscov2specificantibodiesincancerpatientsundergoingactivesystemictreatmentasinglecenterexperiencefromthemarcheregionitaly |